Sanofi has agreed a €45 per share cash deal to acquire Ablynx NV, representing a total deal value of about €3.9bn. The Belgian firm has accepted the offer, after rejecting bids from the Danish diabetes and hemophilia therapy maker Novo Nordisk AS over the past few weeks. Novo's most recent disclosed all-cash bid was worth €2.6bn, 50% lower than Sanofi's. (Also see "Novo Nordisk Offers €2.6bn For Ablynx" - Scrip, 8 January, 2018.)
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.